These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Safety and convenience of continuous warfarin strategy during the periprocedural period in patients who underwent catheter ablation of atrial fibrillation. Kwak JJ; Pak HN; Jang JK; Kim SK; Park JH; Choi JI; Hwang C; Kim YH J Cardiovasc Electrophysiol; 2010 Jun; 21(6):620-5. PubMed ID: 20039992 [TBL] [Abstract][Full Text] [Related]
6. Periprocedural anticoagulation of patients undergoing pericardiocentesis for cardiac tamponade complicating catheter ablation of atrial fibrillation. Lin T; Bai R; Chen YW; Yu RH; Tang RB; Sang CH; Li SN; Ma CS; Dong JZ Int Heart J; 2015; 56(1):56-61. PubMed ID: 25503659 [TBL] [Abstract][Full Text] [Related]
7. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. Lakkireddy D; Reddy YM; Di Biase L; Vallakati A; Mansour MC; Santangeli P; Gangireddy S; Swarup V; Chalhoub F; Atkins D; Bommana S; Verma A; Sanchez JE; Burkhardt JD; Barrett CD; Baheiry S; Ruskin J; Reddy V; Natale A J Am Coll Cardiol; 2014 Mar; 63(10):982-8. PubMed ID: 24412445 [TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of bridging therapy with fondaparinux versus low-molecular-weight heparin in patients undergoing atrial fibrillation ablation. Zhang F; Zhao D; Peng X; Yang H; Zhu T; Huang F; Peng J Nan Fang Yi Ke Da Xue Xue Bao; 2014 Apr; 34(4):448-52. PubMed ID: 24752085 [TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. Nin T; Sairaku A; Yoshida Y; Kamiya H; Tatematsu Y; Nanasato M; Inden Y; Hirayama H; Murohara T Pacing Clin Electrophysiol; 2013 Feb; 36(2):172-9. PubMed ID: 23121681 [TBL] [Abstract][Full Text] [Related]
11. The use of dabigatran immediately after atrial fibrillation ablation. Winkle RA; Mead RH; Engel G; Kong MH; Patrawala RA J Cardiovasc Electrophysiol; 2012 Mar; 23(3):264-8. PubMed ID: 21955008 [TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Douketis JD; Johnson JA; Turpie AG Arch Intern Med; 2004 Jun; 164(12):1319-26. PubMed ID: 15226166 [TBL] [Abstract][Full Text] [Related]
13. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. Eitel C; Koch J; Sommer P; John S; Kircher S; Bollmann A; Arya A; Piorkowski C; Hindricks G Europace; 2013 Nov; 15(11):1587-93. PubMed ID: 23703362 [TBL] [Abstract][Full Text] [Related]
14. No increased bleeding events with continuation of oral anticoagulation therapy for patients undergoing cardiac device procedure. Li HK; Chen FC; Rea RF; Asirvatham SJ; Powell BD; Friedman PA; Shen WK; Brady PA; Bradley DJ; Lee HC; Hodge DO; Slusser JP; Hayes DL; Cha YM Pacing Clin Electrophysiol; 2011 Jul; 34(7):868-74. PubMed ID: 21410724 [TBL] [Abstract][Full Text] [Related]
15. Catheter ablation for atrial fibrillation on uninterrupted warfarin: can it be done without echo guidance? Page SP; Siddiqui MS; Finlay M; Hunter RJ; Abrams DJ; Dhinoja M; Earley MJ; Sporton SC; Schilling RJ J Cardiovasc Electrophysiol; 2011 Mar; 22(3):265-70. PubMed ID: 21040095 [TBL] [Abstract][Full Text] [Related]
16. Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation. Gautam S; John RM; Stevenson WG; Jain R; Epstein LM; Tedrow U; Koplan BA; McClennen S; Michaud GF J Cardiovasc Electrophysiol; 2011 Mar; 22(3):248-54. PubMed ID: 20812929 [TBL] [Abstract][Full Text] [Related]
17. Uninterrupted Direct Oral Anticoagulant and Warfarin Administration in Elderly Patients Undergoing Catheter Ablation for Atrial Fibrillation: A Comparison With Younger Patients. Yanagisawa S; Inden Y; Fujii A; Ando M; Funabiki J; Murase Y; Takenaka M; Otake N; Ikai Y; Sakamoto Y; Shibata R; Murohara T JACC Clin Electrophysiol; 2018 May; 4(5):592-600. PubMed ID: 29798785 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation. Nagao T; Inden Y; Shimano M; Fujita M; Yanagisawa S; Kato H; Ishikawa S; Miyoshi A; Okumura S; Ohguchi S; Yamamoto T; Yoshida N; Hirai M; Murohara T Pacing Clin Electrophysiol; 2015 Feb; 38(2):155-63. PubMed ID: 25487164 [TBL] [Abstract][Full Text] [Related]
19. Renal function and risk of stroke and bleeding in patients undergoing catheter ablation for atrial fibrillation: Comparison between uninterrupted direct oral anticoagulants and warfarin administration. Yanagisawa S; Inden Y; Fujii A; Ando M; Funabiki J; Murase Y; Takenaka M; Otake N; Ikai Y; Sakamoto Y; Shibata R; Murohara T Heart Rhythm; 2018 Mar; 15(3):348-354. PubMed ID: 29107192 [TBL] [Abstract][Full Text] [Related]
20. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Wazni OM; Beheiry S; Fahmy T; Barrett C; Hao S; Patel D; Di Biase L; Martin DO; Kanj M; Arruda M; Cummings J; Schweikert R; Saliba W; Natale A Circulation; 2007 Nov; 116(22):2531-4. PubMed ID: 17998456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]